Profile picture

Mr Daniel Scheidet

Heidelberg (Germany)
Follow
Logo ESC

Contributor content

Cardiac biomarkers and cardiovascular side effects are associated with a reduced mortality of oncological patients receiving BRAF/MEK-Inhibitor therapy
Presentation
Cardiac biomarkers and cardiovascular side effects are associated with a reduced mortality of oncological patients receiving BRAF/MEK-Inhibitor therapy
Read more

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources